Abstracts tagged "C1q"

Abstract Number: 1744 • 2016 ACR/ARHP Annual Meeting
Expression of C1q By Podocytes at Late Stages of Proliferative Lupus Glomerulonephritis
Hongyang Wang¹, Ou Jin², Niansheng Yang³, Chao Dai¹, Sun-sang Sung¹, Felicia Gaskin⁴ and Shu Man Fu⁵, ¹Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, ²Rheumatology, Sun Yat-sen University Third Affiliated Hospital, Guangzhou, China, ³Rheumatology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China, ⁴Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, ⁵Department of Medicine, University of Virginia, Charlottesville, VA
Background/Purpose: In NZM2328 (NZM), a mouse model of proliferative lupus glomerulonephritis (GN), lupus GN can be categorized to four stages, i.e. normal, acute GN (aGN),…
Abstract Number: 1747 • 2016 ACR/ARHP Annual Meeting
Dissecting the Role of Single Complement Deficiencies in a Novel Model for Apoptotic Cell-Induced Lupus
Lucrezia Colonna¹, Clayton J. Sontheimer², Lena M. Tanaka³, Kelly L. Hudkins⁴, Charles E. Alpers⁴, Keith B. Elkon¹ and YuFeng Peng³, ¹Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ²Pediatric Rheumatology, University of Washington, Seattle, WA, ³Division of Rheumatology, University of Washington, Seattle, WA, ⁴Pathology, University of Washington, Seattle, WA
Background/Purpose: The role of complement in Systemic Lupus Erythematosus (SLE) is complex as complement deficiencies in early components of the classical pathway cause lupus with…
Abstract Number: 2036 • 2016 ACR/ARHP Annual Meeting
Whole Exome Sequencing in Early Onset Systemic Lupus Erythematosus
Ezgi Deniz Batu¹, Can Kosukcu², Ekim Z. Taskiran², Sema Akman³, Kubra Ozturk⁴, Betul Sozeri⁵, Erbil Unsal⁶, Zelal Ekinci⁴, Yelda Bilginer⁷, Mehmet Alikasifoglu² and Seza Ozen⁸, ¹Department of Pediatrics, Divison of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ²Department of Medical Genetics, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ³Department of Pediatrics, Division of Nephrology-Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ⁴Department of Pediatrics, Division of Rheumatology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ⁵Pediatric Rheumatology, Erciyes University Faculty of Medicine, Kayseri, Turkey, ⁶Dokuz Eylul University, Izmir, Turkey, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁸Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disorder with different genetic and environmental factors playing role in its pathogenesis. Early onset SLE, familial…
Abstract Number: 2958 • 2016 ACR/ARHP Annual Meeting
Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden
Christopher Sjöwall¹, Thomas Mandl² and Aladdin Mohammad^3,4, ¹Linköping University, Department of Clinical and Experimental Medicine Rheumatology/AIR, Linköping, Sweden, ²Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, ³Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Rheumatology, Lund, Sweden, Lund, Sweden, ⁴Addenbrooke’s Hospital, Vasculitis and Lupus Clinic, Cambridge, UK, Cambridge, United Kingdom
Background/Purpose: Since first described by McDuffie et al. in 1973, hypocomplementemic urticarial vasculitis (HUV) syndrome has been recognized as a specific autoimmune disorder involving at…
Abstract Number: 2777 • 2014 ACR/ARHP Annual Meeting
Clinical-Biological Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data from a French Nationwide Study on 57 Patients
Marie Jachiet¹, Alain Le Quellec², Alban Deroux³, Pascal Godmer⁴, Mikael Ebbo⁵, Leonardo Astudillo⁶, Beatrice Flageul⁷, Nicolas Dupin⁸, Selim Aractingi¹, Loïc Guillevin for the French Vasculitis Study Group⁹, Luc Mouthon⁹ and Benjamin Terrier¹⁰, ¹Dermatology, Cochin Hospital, Paris, France, ²Division of internal Medicine, Hôpital Saint-Eloi, Centre Hospitalier Universitaire de Montpellier, Montpellier, Montpellier, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ⁵Internal Medicine, CHU, Marseille, France, ⁶Internal Medicine, CHU, Toulouse, France, ⁷Dermatology, Saint Louis, Paris, France, ⁸Service de Dermatologie, Hôpital Cochin, AP-HP, Paris, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁰National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose Hypocomplementemic urticarial vasculitis (HUV), an uncommon vasculitis of unknown etiology, is rarely reported. It is also called anti-C1q vasculitis in the 2012 revised International…
Abstract Number: 1618 • 2014 ACR/ARHP Annual Meeting
Suppression of IFN-α Production from Systemic Lupus Erythematosus Immune Complexes Via C1 Complex Enzymatic Properties
Jing Yao Leong¹, Joo Guan Yeo¹, Thaschawee Arkachaisri² and Jinhua Lu³, ¹Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, ²Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ³Microbiology Department, National University of Singapore, Singapore, Singapore
Background/Purpose Systemic Lupus Erythematosus (SLE) is an autoimmune disease associated with the development of auto-antibodies particularly against nuclear antigens. Previous studies have revealed the possible…
Abstract Number: 938 • 2014 ACR/ARHP Annual Meeting
C1q Is Mandatory for Disease Development in Experimental Arthritis and Expression of Its Receptors Correlates with Disease Activity in Patients
Matthieu Ribon¹, Julie Mussard¹, Roxane Herve¹, Marina Botto², Marie-Christophe Boissier³ and Patrice Decker¹, ¹INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, ²Centre for Complement & Inflammation Research, Imperial College, London, United Kingdom, ³INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France
Background/Purpose The complement system is a major effector mechanism of innate and adaptive immunity. It is activated in rheumatoid arthritis (RA) patients but the pathway…
Abstract Number: 17 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Against Component Of Complement One Contribute To The Complement Activation and Clinical Manifestation Of Antiphospholipid Syndrome (APS) Especially In Refractory Cases
Kenji Oku¹, Olga Amengual¹, Ikuma Nakagawa¹, Toshiyuki Watanabe², Yusaku Kanetsuka¹, Toshiyuki Bohgaki¹, Tetsuya Horita¹, Shinsuke Yasuda¹ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Background/Purpose: In the pathogenic mechanisms of antiphospholipid syndrome (APS), it is recognized that pathogenicity of antiphospholipid antibodies (aPL) has dominant effects. Complement is the part…
Abstract Number: 2521 • 2012 ACR/ARHP Annual Meeting
Immunoglobulin G Fc Receptor Activity in Vivo Is Under Complement Control
Eveline Y. Wu¹, Haixiang Jiang², C. Garren Hester³ and Michael M. Frank², ¹DUMC Box 3212, Duke Univ Med Ctr, Durham, NC, ²Pediatrics, Duke Univ Med Ctr, Durham, NC, ³Duke Univ Med Ctr, Durham, NC
Background/Purpose: Immunoglobulin G receptors (FcγR) are critical in the development of autoimmunity and pathogenesis of immune complex (IC) diseases. Although ICs activate complement, contributing to…
Abstract Number: 1637 • 2012 ACR/ARHP Annual Meeting
A Novel Peptide Inhibiting the Binding Between C1q and Immunoglobulin Ameliorates Joint Destruction in Rats with Collagen-Induced Arthritis
Yu Moriguichi and Tetsuya Tomita, Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: C1q is the major subcomponent of the first component of complement protein. The activation of the complement is triggered by binding of C1q to…
Abstract Number: 661 • 2012 ACR/ARHP Annual Meeting
Co-Localization of C-Reactive Protein, Immunoglobulin G and Complement in Renal Subendothelial Immune Deposits of Proliferative Lupus Nephritis Detected Using Immunogold Electron Microscopy
Christopher Sjöwall¹, Anders I. Olin², Thomas Skogh³, Jonas Wetterö⁴, Mattias Mörgelin², Ola Nived⁵, Gunnar Sturfelt⁶ and Anders A. Bengtsson⁷, ¹Deparment of clinical and experimental medicine, Linkoping University, Linkoping, Sweden, ²Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden, Lund, Sweden, ³Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁴Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ⁵Department of Rheumatology, University Hospital Lund, Lund, Sweden, ⁶Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁷Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: The pattern recognition molecules C-reactive protein (CRP) and complement protein 1q (C1q) are pivotal parts of the innate immune system and display relevant biological…
Abstract Number: 662 • 2012 ACR/ARHP Annual Meeting
Increased C1q, C4 and C3 Deposition On Platelets in Patients with Systemic Lupus Erythematosus – A Possible Link to Venous Thrombosis?
Christian Lood¹, Sam Eriksson¹, Birgitta Gullstrand², Andreas Jönsen¹, Gunnar Sturfelt³, Lennart Truedsson² and Anders A. Bengtsson⁴, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, ²Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing vascular diseases (VD) such as myocardial infarction, stroke and venous thrombosis, which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].